AHA Scientific Sessions 2024 Industry Programming Guide

Event listings current as of Thursday, Oct. 25, 2024. Visit the Mobile Meeting Guide App for more details. 11 2024 INDUSTRY EVENTS Antiarrhythmic Drugs in Atrial Fibrillation: Putting the Guideline Into Practice 11:15 a.m.-12 p.m. Learning Studio I SUPPORTER: Sanofi Evaluating Long-Term Outcomes and Real-World Impact of Cardiac Myosin Inhibition in Adults With Symptomatic NYHA Class II-III Obstructive HCM 11:15 a.m.-12 p.m. Heart Theater I SUPPORTER: Bristol-Myers Squibb Managing LDL-C With LEQVIO® (inclisiran) After a Recent Coronary Event: Putting Evidence Into Practice 11:15 a.m.-12 p.m. Learning Studio II SUPPORTER: Novartis Pharmaceutical Corporation A New Era in the Treatment of Hypertension 11:15 a.m.-12 p.m. Heart Theater II SUPPORTER: Idorsia Pharmaceuticals Ltd A Development for Adults With Pulmonary Arterial Hypertension 12:30-1:15 p.m. Learning Studio I SUPPORTER: Merck & Co. Address the Gap: Elevate Care for CVD With Urgent LDL-C Management 12:30-1:15 p.m. Learning Studio II SUPPORTER: Amgen Inc GDMT and Hyperkalemia: A Crossroad for Cardiology, Finding an Optimal Path 12:30-1:15 p.m. Heart Theater I SUPPORTER: AstraZeneca The Future of AI in Cardiology: Trends, Expert Insights and Panel Discussion 12:30-1:15 p.m. Heart Theater II SUPPORTER: Anumana, Inc. Sunday, Nov. 17

RkJQdWJsaXNoZXIy MjI2NjI=